http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Measuring Multipath Error of a Pseudo Quasi-Zenith Satellite
Toshiaki Tsujii,Hiroshi Tomita,Yoshinori Okuno,Ivan Petrovski,Masahiro Asako,Kazuki Okano 한국항해항만학회 2006 한국항해항만학회 학술대회논문집 Vol.2 No.-
Japan has been investigating a new satellite based positioning system called Quasi-Zenith Satellite System (QZSS). Since the improvement of positioning availability in urban area is one of the most important advantages of the QZSS, multipath mitigation is a key factor for the QZSS positioning system. Therefore, Japan Aerospace Exploration Agency (JAXA) and GNSS Inc. have commenced the R&D of a pseudolite, which transmits the next-generation signal such as BOC(1,1), in order to evaluate the effect of multipath on the new signal. A prototype BOC pseudolite was developed in 2005, and ground tests showed a capability of generating proper pseudorange. Also, preliminary flight experiments using a pseudo quasi-zenith satellite, a helicopter on which the pseudolite is installed, were conducted in early 2006, and the BOC-type correlation function was monitored in real time.
Immune enhancement effect and radiation protection by royal jelly
Yeunhwa Gu,Yuka Itokawa,Takashi Masubuchi,Masahiro Tomita,Masami Oshima,Takashi Nsakamura,Toshihiro Maenaka,Torao Ishita,Kaori Tano,Yuri Kurono,Hiroyuki Sekimoto,Tetsuo Takeuchi,Kyoo Seok Ahns 한의병리학회 2006 대한동의병리학회 학술대회논문집 Vol.2006 No.9
Endocuff-Assisted versus Cap-Assisted Colonoscopy Performed by Trainees: A Retrospective Study
Yutaka Okagawa,Tetsuya Sumiyoshi,Yusuke Tomita,Shutaro Oiwa,Fumihiro Ogata,Takashi Jin,Masahiro Yoshida,Ryoji Fujii,Takeyoshi Minagawa,Kohtaro Morita,Hideyuki Ihara,Michiaki Hirayama,Hitoshi Kondo 대한소화기내시경학회 2020 Clinical Endoscopy Vol.53 No.3
Background/Aims: The adenoma detection rate (ADR) of screening colonoscopies performed by trainees is often lower than thatof colonoscopies performed by experts. The effcacy of cap-assisted colonoscopy (CAC) in adenoma detection is well documented,especially that of CACs performed by trainees. Endocuff, a new endoscopic cap, is reportedly useful for adenoma detection; however,no trials have compared the effcacy of Endocuff-assisted colonoscopy (EAC) and CAC conducted by trainees. Therefore, the presentstudy retrospectively compared the effcacy between EAC and CAC in trainees. Methods: This was a single-center, retrospective study involving 305 patients who underwent either EAC or CAC performed by threetrainees between January and December 2018. We evaluated the ADR, mean number of adenomas detected per patient (MAP), cecalintubation rate, cecal intubation time, and occurrence of complications between the EAC and CAC groups. Results: The ADR was significantly higher in the EAC group than in the CAC group (54.3% vs. 37.3%, p=0.019), as was the MAP (1.36vs. 0.74, p=0.003). No significant differences were found between the groups with respect to the cecal intubation rate or cecal intubationtime. No major complications occurred in either group. Conclusions: Our results suggest that EAC exhibits increased ADR and MAP compared to CAC when performed by trainees.
Communications Satellite's Development Plan in NASDA and Space Infrastructure "i-Space" Program
Kuroda, Tomonori,Gomi, Jun,Araki, Tsunehiko,Tomita, Eiichi,Maeda, Tsuyoshi,Kadowaki, Naoto,Nakao, Masahiro 통신위성우주산업연구회 2000 Joint Conference on Satellite Communications Vol.2000 No.-
Satellite communications technology has been researched and developed focusing on its merit of "Wide area coverage" and "Broadcasting" for the contribution for the people's living. And, in Japan, consequently, Communications Satellite (CS) and Broadcasting Satellite (BS) are now put to practical use as an infrastructure which will greatly enrich the people's living. The National Space Development Agency of Japan (NASDA) has been working on development and research in communications and broadcasting satellite and its technologies with cooperation and support of other institutions concerned. This paper outlines NASDA's projects of satellite communications mission like Optical Inter-orbit Communications Engineering Test Satellite (OICETS), Data Relay Test Satellite (DRTS) and Engineering Test Satellite-VIII (ETS-VIII) and "i-Space Project", which has been just initiated.
Inamoto, Teruo,Azuma, Haruhito,Nonomura, Norio,Nakatani, Tatsuya,Matsuda, Tadashi,Nozawa, Masahiro,Ueda, Takeshi,Kinoshita, Hidefumi,Nishimura, Kazuo,Kanayama, Hiro-Omi,Miki, Tsuneharu,Tomita, Yoshihi Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.4
Background: In clinical trials with no upper age limit, the proportion of older patients is usually small, probably reflecting the more conservative approach adopted by clinicians when treating the elderly. An exploratory analysis of elderly patients in the RECORD-1 Trial showed that patients ${\geq}$ 65 y.o. had superior median PFS than overall RECORD-1 population (5.4 months and 4.9 months, respectively). We investigated the efficacy, relative benefit and safety of Everolimus (EVE) as sequential therapy after failure of VEGFr-TKI therapy for older patients with metastatic renal cell cancer (mRCC), in daily practice. Materials and Methods: 172 consecutive IRB approved patients with mRCC (median age 65, M:F 135/37, 78% clear cell) who received salvage EVE at 39 tertiary institutions between October 2009 and August 2011 were included in this analysis. Some 31% had progressed on sunitinib, 22% on sorafenib, 1% on axitinib, 41% on sequential therapy, and 5% had received other therapy. Patients with brain metastases were not included and 95% of the patients had a ECOG (Eastern Cooperative Oncology Group) performance status (PS) of 0 or 1. Previous radiotherapy was an exclusion criterion, but prior chemotherapy was permitted. Adequate organ function and hematologic parameters were mandatory. EVE administration was approved by the institutional review board at each participating institution and signed informed consent was obtained from all patients. Results: Median time of the whole cohort to last follow-up was 3.5 months (range 0.4-15.2 months). Forty four percent were continuing to take EVE at last followup. There were 86 (50%) patients ${\geq}$ 65 y.o. and 86 (50%) <65 y.o. The percentage of patients who showed PR/SD was higher in the older group than in the younger one (5.9%/61.2% vs 1.2%/46.5%, respectively). Median survival of older patients was also significantly longer (3.5 +/- 0.31 vs 3.1 +/- 0.34, hazard ratio=0.45, CI; 0.255-0.802). Analysis using Cox regression model adjusted for gender, PS, number of metastases, site of metastases, histology, smoking history and age detected an association between age and PFS (p=0.011). The frequency of adverse events in elderly patients treated with EVE was no greater than that in younger patients, although such toxicity may have had a greater impact on their quality of life. Conclusions: Older patients should not generally be excluded from accepted therapies (mTOR inhibitors after failure of VEGFr-TKI therapy) for mRCC.
Anti-Cancer and Immunological Enhancement in propolis and agaricus blazei murrill
Yeunhwa Gu,Takenori Yamashita,Takashi Namamura,Masami Oshima,Takeo Hasegawa,Kenichi Bamen,Yuicti Mituhana,Hiroshi Ueda,Ikukatsu Suzuki,Sangrea Park,Kyoo Seok Ahn,Tetsuo Takeuchi,Masahiro Tomita 한의병리학회 2004 대한동의병리학회 학술대회논문집 Vol.2004 No.8